INDUCTION ANTI-TNF DRUG LEVELS AND ANTIBODIES AT WEEK 6 IN INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS TREATED WITH INFLIXIMAB

被引：0
|
作者：
Garcia, Karoline S.
Queiroz, Natalia S.
Parra, Rogerio S.
Feres, Omar
Chebli, Julio
Chebli, Liliana A.
Flores, Cristina
Vieira, Andrea
Azevedo, Matheus
Carlos, Alexandre S.
Oba, Jane
Alves, Olivia D.
Ceara, Christianne D.
Sipahi, Aytan M.
Damiao, Aderson O.
机构：
来源：
GASTROENTEROLOGY | 2022年 / 162卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
EP1310
引用
收藏
页码：S1097 / S1097
页数：1
相关论文
共 50 条
  • [1] Induction of antiphospholipid antibodies in patients with inflammatory bowel disease treated with anti-TNFα agents
    Robles, V.
    deGuise, C. Herrera
    Guirola, M. A.
    Borruel, N.
    Casellas, F.
    [J]. JOURNAL OF CROHNS & COLITIS, 2017, 11 : S254 - S255
  • [2] Anti-drug Antibodies Inhibit Neutralization of TNF-alpha in Infliximab Treated Patients with Inflammatory Bowel Disease (IBD)
    Eser, A.
    Vogelsang, H.
    Reinisch, S.
    Novacek, G.
    Dejaco, C.
    Kazemi-Shirazi, L.
    Primas, C.
    Lichtenberger, C.
    Brehovsky, S.
    Singh, S.
    Jain, A.
    Reinisch, W.
    [J]. JOURNAL OF CROHNS & COLITIS, 2015, 9 : S304 - S305
  • [3] Clinical utility of routine measurement of Anti-TNF levels and their antibodies in inflammatory bowel disease (IBD)
    Sarwar, S.
    Foster, K.
    Corn, E.
    Moss, S.
    [J]. JOURNAL OF CROHNS & COLITIS, 2015, 9 : S297 - S297
  • [4] Measurement of Anti-TNF Agents and Anti-Drug Antibodies Serum Levels in Patients with Inflammatory Bowel Disease
    Guerra, Ivan
    Chaparro, Maria
    Bermejo, Fernando
    Gisbert, Javier P.
    [J]. CURRENT DRUG METABOLISM, 2014, 15 (09) : 875 - 881
  • [5] Anti-TNF levels and anti-drug antibodies, immunosuppressants and clinical outcomes in inflammatory bowel disease
    Ha, Christina
    Mathur, Jagrati
    Kornbluth, Asher
    [J]. EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2015, 9 (04) : 497 - 505
  • [6] ANTI-TNF DRUG AND ANTIBODY TESTING AT WEEK 30 IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: IS IT WORTHWHILE?
    Boal, A.
    Squires, S. I.
    Naismith, G. D.
    [J]. GUT, 2017, 66 : A257 - A258
  • [7] A retrospective analysis of outcomes for anti-TNF naive inflammatory bowel disease patients treated with adalimumab or infliximab
    Hyland, S.
    Keegan, D.
    Mulcahy, H.
    Doherty, G.
    Cullen, G.
    [J]. IRISH JOURNAL OF MEDICAL SCIENCE, 2015, 184 : S58 - S58
  • [8] Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies
    Beigel, Florian
    Steinborn, Anni
    Schnitzler, Fabian
    Tillack, Cornelia
    Breiteneicher, Simone
    John, Jestinah Mahachie
    Van Steen, Kristel
    Laubender, Ruediger P.
    Goeke, Burkhard
    Seiderer, Julia
    Brand, Stephan
    Ochsenkuehn, Thomas
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 (07) : 735 - 744
  • [9] A FCGR3A Polymorphism Predicts Anti-drug Antibodies in Chronic Inflammatory Bowel Disease Patients Treated With Anti-TNF
    Romero-Cara, Patricia
    Torres-Moreno, Daniel
    Pedregosa, Jose
    Antonio Vilchez, Juan
    Sergia Garcia-Simon, Maria
    Ruiz-Merino, Guadalupe
    Moran-Sanchez, Senador
    Conesa-Zamora, Pablo
    [J]. INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 2018, 15 (01): : 10 - 15
  • [10] HLA-DQA1*05 and development of anti-drug antibodies in anti-TNF treated patients with inflammatory bowel disease
    Lopez-Blanco, Ruben
    Mendez-Lopez, Isabel-Maria
    Recio-Romero, Rafael
    Luque-Fernandez, Rosario
    Caballero-Gonzalez, Abelardo
    Torio-Ruiz, Alberto
    [J]. HLA, 2022, 99 (05) : 539 - 540
12345